Cancer is currently the leading cause of death worldwide according to the World Health Organization1. In 2007, approximately 7.9 million people died of cancer and over 12 million new cases are diagnosed each year. As a result, cancer is the world’s most costly disease2. In terms of disability and years of life lost, cancer’s global economic toll was $895 billion (1.5% of world GDP) in 2008. In the U.S., the National Institutes of Health estimates overall cancer costs in 2010 at $264 billion, i.e. $103 billion for direct medical costs and $161 billion due to indirect costs associated with loss of productivity to illness and death3.
Almost everyone has experienced the devastating heartache of cancer either as a patient or with the loss of loved family members or close friends.
Bexion’s Elegant Solution
New research findings on BXQ-350 nanovesicles for the diagnosis and treatment of cancer in laboratory animals are very promising. The anti-cancer activity of BXQ-350 nanovesicles was discovered and first published by researchers at Cincinnati Children’s Hospital Medical Center4. These researchers showed that BXQ-350 nanovesicles killed human brain, nerve, and breast cancer cells in test tubes. They also showed that BXQ-350 nanovesicles stopped the growth of human brain and nerve cancers transplanted into mice with no observable adverse effects after 5 weeks of dosing.
Additional unpublished research sponsored by Bexion Pharmaceuticals has shown that BXQ-350 nanovesicles kills over 60 different types of human cancer cells in test tubes. By adding a dye to BXQ-350 nanovesicles, the Bexion scientists have been able to visualize penetration of the drug into several different types of cancers in rats and mice including pancreas, breast and brain cancers, with no penetration into healthy tissues. Of importance, BXQ-350 treatment significantly increased (doubled) survival times for many mice with either brain or pancreatic cancer. Sixty-seven (67%) of mice with pancreatic cancer survived with BXQ-350 treatment. In total, BXQ-350 nanovesicles have been shown to be highly effective for treating cancer in 7 different mouse cancer models. In these extensive pre-clinical (animal) studies, there have been no observable significant adverse effects on animal behavior, body weight, food consumption, organ weights, clinical pathology blood tests, or tissue pathology.
As a result of these exciting pre-clinical findings, the National Cancer Institute (NCI) has selected Bexion Pharmaceuticals as a collaborative research partner to advance research on BXQ-350 nanovesicle treatment of cancer. The purpose of this partnership is to speed the generation of scientific data needed for filing an investigative new drug (IND) application to the U.S. Food & Drug Administration (FDA).
If similar results are found in human cancer patients, BXQ-350 nanovesicle treatment of cancer could provide considerable potential benefits to affected patients.
1World Health Organization. Quick cancer facts. WHO, Geneva, Switzerland http://www.who.int/cancer/en/
2Marchione, M. Cancer is the world’s costliest disease. Associated Press. August 17, 2010 http://www.foxnews.com/health/2010/08/17/report-cancer-worlds-costliest-disease/
3American Cancer Society. Cancer facts and figures 2010. ACS, Atlanta, GA, USA, 2010. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-2010
4Qi X., Chu Z., Mahller Y., Stringer K., Witte D., Cripe T. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal Saposin C protein. Clin Cancer Res. 15(18): 5840-5851, 2009.